Literature DB >> 21716271

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

S A Scott1, K Sangkuhl, E E Gardner, C M Stein, J-S Hulot, J A Johnson, D M Roden, T E Klein, A R Shuldiner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21716271      PMCID： PMC3234301          DOI： 10.1038/clpt.2011.132

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  30 in total

1.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors:  M V Relling; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.

Authors:  Klaus A Tiroch; Dirk Sibbing; Werner Koch; Tobias Roosen-Runge; Julinda Mehilli; Albert Schömig; Adnan Kastrati
Journal:  Am Heart J       Date:  2010-09       Impact factor: 4.749

3.  The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.

Authors:  K A Kim; P W Park; S J Hong; J-Y Park
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

4.  The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects.

Authors:  K Umemura; T Furuta; K Kondo
Journal:  J Thromb Haemost       Date:  2008-06-04       Impact factor: 5.824

5.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

Authors:  Jean-Sébastien Hulot; Alessandra Bura; Eric Villard; Michel Azizi; Véronique Remones; Catherine Goyenvalle; Martine Aiach; Philippe Lechat; Pascale Gaussem
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

6.  Paraoxonase-1 is a major determinant of clopidogrel efficacy.

Authors:  Heleen J Bouman; Edgar Schömig; Jochem W van Werkum; Janna Velder; Christian M Hackeng; Christoph Hirschhäuser; Christopher Waldmann; Hans-Günther Schmalz; Jurriën M ten Berg; Dirk Taubert
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

7.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Authors:  Matthew J Price; Peter B Berger; Paul S Teirstein; Jean-François Tanguay; Dominick J Angiolillo; Douglas Spriggs; Sanjeev Puri; Mark Robbins; Kirk N Garratt; Olivier F Bertrand; Michael E Stillabower; Michael E Stillablower; Joseph R Aragon; David E Kandzari; Curtiss T Stinis; Michael S Lee; Steven V Manoukian; Christopher P Cannon; Nicholas J Schork; Eric J Topol
Journal:  JAMA       Date:  2011-03-16       Impact factor: 56.272

8.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

9.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

Authors:  J T Brandt; S L Close; S J Iturria; C D Payne; N A Farid; C S Ernest; D R Lachno; D Salazar; K J Winters
Journal:  J Thromb Haemost       Date:  2007-09-26       Impact factor: 5.824

10.  Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.

Authors:  Lars Wallentin; Christoph Varenhorst; Stefan James; David Erlinge; Oscar O Braun; Joseph A Jakubowski; Atsuhiro Sugidachi; Kenneth J Winters; Agneta Siegbahn
Journal:  Eur Heart J       Date:  2007-11-30       Impact factor: 29.983
View more
  151 in total

Review 1.  CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis.

Authors:  Xuan Niu; Ling Mao; Yan Huang; Suraj Baral; Jian-Yong Li; Yuan Gao; Yuan-Peng Xia; Quan-Wei He; Meng-Die Wang; Man Li; Li Zou; Xiao-Ping Miao; Bo Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

2.  Pharmacogenetic testing: Current Evidence of Clinical Utility.

Authors:  Jivan Moaddeb; Susanne B Haga
Journal:  Ther Adv Drug Saf       Date:  2013-08-01

Review 3.  [Pharmacogenetics. Clinical relevance in anesthsiology].

Authors:  E M Zeidler; A E Goetz; C Zöllner
Journal:  Anaesthesist       Date:  2013-11       Impact factor: 1.041

Review 4.  Pharmacogenetics and individualizing drug treatment during pregnancy.

Authors:  David M Haas
Journal:  Pharmacogenomics       Date:  2014-01       Impact factor: 2.533

5.  Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset.

Authors:  Adam S Gordon; Holly K Tabor; Andrew D Johnson; Beverly M Snively; Themistocles L Assimes; Paul L Auer; John P A Ioannidis; Ulrike Peters; Jennifer G Robinson; Lara E Sucheston; Danxin Wang; Nona Sotoodehnia; Jerome I Rotter; Bruce M Psaty; Rebecca D Jackson; David M Herrington; Christopher J O'Donnell; Alexander P Reiner; Stephen S Rich; Mark J Rieder; Michael J Bamshad; Deborah A Nickerson
Journal:  Hum Mol Genet       Date:  2013-11-26       Impact factor: 6.150

6.  Hypoxia and Ischemia Promote a Maladaptive Platelet Phenotype.

Authors:  Scott J Cameron; Doran S Mix; Sara K Ture; Rachel A Schmidt; Amy Mohan; Daphne Pariser; Michael C Stoner; Punit Shah; Lijun Chen; Hui Zhang; David J Field; Kristina L Modjeski; Sandra Toth; Craig N Morrell
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-05-03       Impact factor: 8.311

7.  Pharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug?

Authors:  David M Haas; Mary DʼAlton
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

8.  Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population.

Authors:  Carmelo Orengo-Mercado; Bianca Nieves; Lizbeth López; Nabila Vallés-Ortiz; Jessicca Y Renta; Pedro J Santiago-Borrero; Carmen L Cadilla; Jorge Duconge
Journal:  J Pharmacogenomics Pharmacoproteomics       Date:  2013-03-27

9.  Using Workflow Modeling to Identify Areas to Improve Genetic Test Processes in the University of Maryland Translational Pharmacogenomics Project.

Authors:  Elizabeth M Cutting; Casey L Overby; Meghan Banchero; Toni Pollin; Mark Kelemen; Alan R Shuldiner; Amber L Beitelshees
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

Review 10.  Relating human genetic variation to variation in drug responses.

Authors:  Ashraf G Madian; Heather E Wheeler; Richard Baker Jones; M Eileen Dolan
Journal:  Trends Genet       Date:  2012-07-26       Impact factor: 11.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.